Soleno Therapeutics, Inc. Series A Warrant
SLNOW
SLNOW was delisted on the 8th of November, 2019.
2 hedge funds and large institutions have $24K invested in Soleno Therapeutics, Inc. Series A Warrant in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
71% less capital invested
Capital invested by funds: $82K → $24K (-$58K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$100 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $23K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $1K | +$100 | +455 | +4% |
|
SLNOW Hedge Fund Activity: Q3 2018 in Review
2 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics, Inc. Series A Warrant (SLNOW) for Q3 2018, worth a combined $24K — down 71% from $82K a quarter earlier.
Fund positioning in SLNOW was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $100.
- 2 institutional investors held Soleno Therapeutics, Inc. Series A Warrant (SLNOW) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $24K of Soleno Therapeutics, Inc. Series A Warrant stock for Q3 2018, down 71% quarter-over-quarter.
- 0 funds opened new Soleno Therapeutics, Inc. Series A Warrant positions in Q3 2018 and 0 closed out.
- The largest Soleno Therapeutics, Inc. Series A Warrant buyer in Q3 2018 was UBS Group, an estimated $100 added.
Based on aggregated 13F filings for Q3 2018.